| # | Drug | Count |
|---|---|---|
| 0 | PREDNISONE | 46 |
| 1 | TACROLIMUS | 37 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 35 |
| 3 | TACROLIMUS OINTMENT 0.1% | 35 |
| 4 | MYCOPHENOLATE MOFETIL | 30 |
| 5 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 30 |
| 6 | EMPAGLIFLOZIN | 29 |
| 7 | CARBOPLATIN | 21 |
| 8 | PACLITAXEL | 21 |
| 9 | PACLITAXEL (AIBUMIN-BOUND) | 21 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | METYROSINE | 1 | 0.0123 |
| 1 | ANORECTAL OINTMENT | 1 | 0.0046 |
| 2 | BETAXOLOL HYDROCHLORIDE | 1 | 0.0019 |
| 3 | AMPICILLIN AND SULBACTAM | 1 | 0.0011 |
| 4 | SATRALIZUMAB | 2 | 0.0011 |
| 5 | FLUTAMIDE | 1 | 0.0010 |
| 6 | METYRAPONE | 1 | 0.0010 |
| 7 | PIOGLITAZONE HYDROCHLORIDE | 1 | 0.0008 |
| 8 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 9 | HYALURONATE SODIUM | 1 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 86 |
| 1 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 43 |
| 2 | Platinum-based Drug [EPC] | 23 |
| 3 | Microtubule Inhibitor [EPC] | 21 |
| 4 | Proton Pump Inhibitor [EPC] | 18 |
| 5 | Loop Diuretic [EPC] | 16 |
| 6 | Insulin Analog [EPC] | 13 |
| 7 | Kinase Inhibitor [EPC] | 13 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 12 |
| 9 | Aldosterone Antagonist [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Catecholamine Synthesis Inhibitor [EPC] | 1 | 0.0123 |
| 1 | Adrenal Steroid Synthesis Inhibitor [EPC] | 1 | 0.0010 |
| 2 | Complement 5a Receptor Antagonist [EPC] | 4 | 0.0006 |
| 3 | Antiseptic [EPC] | 2 | 0.0005 |
| 4 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 43 | 0.0004 |
| 5 | Phosphodiesterase 3 Inhibitor [EPC] | 2 | 0.0003 |
| 6 | Somatostatin Analog [EPC] | 2 | 0.0003 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 6 | 0.0003 |
| 8 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 9 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 2 | 0.0002 |